@article{d326c45af4d7480eacc5f63f5718f22f,
title = "Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis",
keywords = "DOUBLE-BLIND, MULTICENTER TRIAL, CANCER-RISK, CD20, DEMYELINATION, PATHOLOGY, ANTIBODY, DAMAGE",
author = "{ORATORIO Clinical Investigators} and Xavier Montalban and Hauser, {Stephen L} and Ludwig Kappos and Arnold, {Douglas L} and Amit Bar-Or and Giancarlo Comi and {de Seze}, J{\'e}r{\^o}me and Gavin Giovannoni and Hans-Peter Hartung and Bernhard Hemmer and Fred Lublin and Rammohan, {Kottil W} and Krzysztof Selmaj and Anthony Traboulsee and Annette Sauter and Donna Masterman and Paulo Fontoura and Shibeshih Belachew and Hideki Garren and Nicole Mairon and Peter Chin and Wolinsky, {Jerry S} and Peter Wipfler",
note = "Wipfler: study gr member, ohne Affiliation",
year = "2017",
doi = "10.1056/NEJMoa1606468",
language = "English",
volume = "376",
pages = "209--220",
journal = "NEW ENGLAND JOURNAL OF MEDICINE ",
issn = "0028-4793",
publisher = "Massachusetts Medical Soc",
number = "3",
}